Aytu BioPharma Return on Equity

Aytu BioPharma (AYTU) currently reports a ROE of -96.9%. That is below the Healthcare sector average of 29.33%. Use the charts on this page to explore Aytu BioPharma's ROE history and peer comparisons.

Aytu BioPharma's ROE of -96.9% is lower than the Healthcare sector average of 29.33%. That is roughly 430.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Aytu BioPharma's current -96.9% should be judged against Healthcare norms (sector average: 29.33%) and against AYTU's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -96.9%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.33%. From there, open related valuation or income-statement pages for Aytu BioPharma, and consider following AYTU for alerts when major investors trade the stock.

Aytu BioPharma is classified in the Healthcare sector. On ROE, it currently shows -96.9% versus a sector average near 29.33%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AYTU with unrelated industries.